Market Overview

Analyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts?

Analyst: Is The Street Ignoring Pfizer And Its Upcoming Catalysts?
Related PFE
Benzinga's Top Upgrades, Downgrades For December 11, 2018
A Peek Into The Markets: US Stock Futures Surge Ahead Of Producer Price Index
Time To Connect The Dots (Stocks To Watch Podcast) (Seeking Alpha)

Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors.

The Analyst

Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target.

The Thesis

Pfizer's pipeline represents "new and significant" market opportunities that are "ignored" by Wall Street analysts despite clear multiple upcoming catalysts, Purkiss said in a Sunday note. The analyst's 2023 revenue forecast stands $10.7 billion ahead of the consensus estimate.

Here is a summary which shows the disparity between Purkiss' 2023 revenue estimates and the Street's estimates: 


  • Ibrance: $12.876 billion versus the Street's $6.926 billion.
  • Eliquis: $5.229 billion versus the Street's $4.573 billion.
  • Xeljanz: $3.409 billion versus the Street's $2.415 billion.
  • Xtandi: $2.093 billion versus the Street's $1.6 billion.
  • Bosulif: $636 million versus the Street's $460 million.


Specific catalysts that Purkiss said may be ignored by the Street but should support these key growth assets include: 1) the potential readout of PALLET (early 2018), 2) potential readout of PROSPER (also early 2018), 3) potential approval for Xeljanz in PsA (PDUFA in December 2017) and 4) Bosulif in 1L CML (PDUFA also in December 2017).

Price Action

Shares of Pfizer were trading up slightly at $35.25 Monday and are up 8 percent over the past year.

Related Links:

Pfizer Should Outperform, Morgan Stanley Upgrades

Analyst Prescribes Neutral Rating For Pfizer Shares

Latest Ratings for PFE

Dec 2018JP MorganDowngradesOverweightNeutral
Nov 2018CitigroupMaintainsSellSell
Nov 2018BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Cancer Drugs eliquisAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga


Related Articles (PFE)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Cramer's 'Biggest Mistake'? Owning General Electric's Stock

What The New GOP Tax Plan Could Mean For Fannie Mae, Freddie Mac